Cost‐effectiveness of imatinib versus interferon‐α plus low‐dose cytarabine for patients with newly diagnosed chronic‐phase chronic myeloid leukemia - Concepedia

Concepedia

Publication | Open Access

Cost‐effectiveness of imatinib versus interferon‐α plus low‐dose cytarabine for patients with newly diagnosed chronic‐phase chronic myeloid leukemia

DOI Full Paper Access

77

Citations

39

References

2004

Year

Shelby D. Reed, Kevin J. Anstrom, J Ludmer, G. Alastair Glendenning, Kevin A. Schulman

Abstract

The results of the current study demonstrate that compared with IFN+LDAC, imatinib is a cost-effective first-line therapy in patients with newly diagnosed chronic-phase CML.

References

	Year	Citations

Page 1